Navigation Links
Stroma genomic signature predicts resistance to anthracyclin-based chemotherapy in breast cancer
Date:2/3/2009

Researchers at the Swiss Institute of Bioinformatics and the Swiss National Center of Competence in Research in Molecular Oncology in Lausanne have developed a new test to predict how breast cancer patients respond to chemotherapy, which could help change how treatment is delivered in the future. In an article, 'A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer' i, published in Nature Medicine, Dr Pierre Farmer and colleagues showed the potential of the reactive stroma to modulate tumor phenotype and the clinical response to treatment. This is a major step forward in the field as identifying factors that influence response to cancer chemotherapy is crucial for improving its efficacy.

The study first started when a team of clinicians, cancer biologists and computational biologists combined their effort to address a very puzzling question: Why breast tumors that have very similar conditions in terms of aggressiveness (grade), invasiveness (node status) and hormone dependency (ER status), respond differently to the same kind of chemotherapy treatment.

"Two breast cancer patients might respond very differently to the same type of chemotherapy although their respective tumors are very similar from a clinical point of view," said Dr Pierre Farmer. "The reasons for these different responses are unknown."

To help find an answer to this question, a collaborative study was set-up within the framework of a large randomized clinical trial that involved more than 40 different hospitals throughout Europe, including those in the UK, France, Belgium, Netherlands, Poland, Sweden and Switzerland. It was led by Professor Herv Bonnefoi of the European Organization for Research and Treatment of Cancer (EORTC) in collaboration with the Swedish Breast Cancer Group (SBCG), the Swiss Cancer Group (SAKK) and the Angloceltic group (ACOG).

In this trial, biopsies were taken from each patient an
'/>"/>

Contact: Janice Blondeau
janice.blondeau@isb-sib.ch
41-216-924-054
Swiss Institute of Bioinoformatics
Source:Eurekalert

1

GOOD

Page: 1 2 3

Related biology news :

1. DNA replication behavior in complex organisms may foreshadow leaps in genomic discoveries
2. UCI and CODA Genomics collaborate to re-engineer yeast for biofuel production
3. Metagenomics of the deep Mediterranean
4. Metagenomics of the deep Mediterranean
5. Inconsistencies with Neanderthal genomic DNA sequences
6. Microarray sequence capture speeds large-scale resequencing of targeted genomic regions
7. NYUs Center for Genomics & Systems Biology receives $4.4 million NSF grant
8. Human RecQ helicases, homologous recombination and genomic instability
9. Virginia Tech plant scientist leads study on genomics of parasitic plants
10. Study finds health professionals, public unprepared for genomic medicine
11. At home genomic tests for disease risk premature

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...LADELPHIA Now in its 32nd year, the CTRC-AACR San...act the best in breast cancer science and world le...eradicating breast cancer. , This year, more th...ather at the Henry B. Gonzales Convention Center i...is a partnership between the American Association ...
(Date:12/3/2009)...est dwellers must be included in the design of the...oid a humanitarian crisis, according to a scientis...n Nature , Dr Simon Lewis argues that at least 50...penhagen, known as REDD (Reducing Emissions from D...orest dwellers directly, and their property rights...
(Date:12/2/2009)...HILADELPHIA Children exposed to secondhand cigare...g cancer in adulthood, even if they never smoked. ...r Epidemiology, Biomarkers & Prevention , a journa... as part of a special tobacco focus in the Decembe...mericans will be diagnosed with lung cancer; more ...
Breaking Biology News(10 mins):CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Over 60 Firms Confirmed to Attend CBIs Third Annual Bio Pharmaceutical Collaboration and Transaction Accounting Conference in September 13715 1Over 60 Firms Confirmed to Attend CBIs Third Annual Bio Pharmaceutical Collaboration and Transaction Accounting Conference in September 13715 2Memorial Blood Centers in Urgent Need of Type O Negative and Type B Negative Blood Donors 55487 1Memorial Blood Centers in Urgent Need of Type O Negative and Type B Negative Blood Donors 55487 2ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 1ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 2ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 3
...nstitute have discovered that a protein known as F...rts of the body may have a function in the regulat...cate tissues that cannot survive the "inflammation...hat this discovery may ultimately help in the deve...h as macular degeneration and autoimmune diseases ...
... Department of Energy,s Pacific Northwest National...e machinery of life -- bringing us one step closer...he environment and protecting the country against ...ed "sequence alignment tool" that can divide the w...ragments so large data sets can run on many proces...
...ity genes by screening the genome of Caenorhabditi...ganism in genetics studies. The findings are repor...h of the 23 genes somehow normally acts to reduce ...eases lifespan. For example, the worm,s lifespan d...operly, and inhibition of another gene increases t...
Other Biology News:A protein in the eye may prevent immune response and protect eyes from disease 2Genomic sequences processed in minutes, rather than weeks 2
(Date:12/2/2009)... , NEW YORK, Dec. 2 Repor...eport is available in its catalogue: ,, Carbon...,, http://www.reportlinker.com/p0164368/Carbon...tml ,, Incubators are the most critical equip...rch, and other applications for providing a contro...
(Date:12/2/2009)... , CALGARY, Dec. 2 /PRNewswire-FirstCall/...ompany") (TSX:ONC; NASDAQ: ONCY ) announced today ...nit offering, the underwriters have exercised in f...dditional 637,500 units. Each unit is comprised of...se warrant, and was sold at a price of US$3.00 per...
(Date:12/2/2009)... , SINGAPORE, Dec. 2 S*BIO... novel oral JAK2 inhibitor, SB1518, at The America...position in New Orleans. ,, Data will be presen...escalation trial of SB1518 detailing its safety, t...K/PD) profile in dose levels ranging from 100 to 6...
(Date:12/2/2009)... The Scientist, a leading scient...hotometrics’ Evolve “Intelligent&rdquo...s “Top 10 Innovations of 2009. , ...lve ™ EMCCD camera from Photometrics ®...CCD and EMCCD cameras for the life sciences, was r...
Breaking Biology Technology:Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3
...., Feb. 3 Genomic Health,Inc. (Nasdaq: GHDX ) t...ess for,the fourth quarter and year ended December...ter of 2008 increased to $31.2 million,compared wi...roduct revenue,from the Oncotype DX(R) breast canc...f 2008, an increase of 60 percent, compared with $...
...Newswire-FirstCall/ - Victhom Human Bionics Inc., ...obionix division has obtained CE Mark approval for... for a closed-loop system (CLS) used on peripheral...eded for the sale of the Neurostep(TM) in any of t...ostep(TM), a fully implantable investigational neu...
...hite Paper Reports More Than 75% of Biotech Firms ...ship in Next Three Years , , NEW YORK, Feb. 3 Mo...plore business partnerships and strategic alliance...ding to "Plumbing the Depths," a new white paper r... www.rkco.com ). Results were based on the finding...
Other Biology Technology:Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 2Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 4Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 5Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 6Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 7Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 8Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 9Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 2Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 3Volatile Economy / Fundraising Challenges Encourage Business Combinations Among Biotech Companies According to New Survey from CPA Firm Rothstein Kass 2Volatile Economy / Fundraising Challenges Encourage Business Combinations Among Biotech Companies According to New Survey from CPA Firm Rothstein Kass 3Volatile Economy / Fundraising Challenges Encourage Business Combinations Among Biotech Companies According to New Survey from CPA Firm Rothstein Kass 4
GR4 Auto Access 100V/50-60Hz from Thermo Scientific
...UF040A is a diluent that is designed for use with ...ies which are paired with a mouse monoclonal coati...d mouse proteins to prevent non-specific binding b...ll; This buffer may be used to stabilize newly c...
EZ-Tn5 Transposase from EPICENTRE Biotechnologies
...BL's bioassays for interferons are cytopathic effe...ral assays. Sample types include; tissue culture ...ormulations. In these assays, one unit is defined...iter to reduce the cytopathic effect of viral infe...
Biology Products: